Rituximab and Hyaluronidase Human Clinical Trials
4 recruitingBiologic
Phase 23Phase 31Phase 11
Showing 1–4 of 4 trials
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled36 locationsNCT05886036
Recruiting
Phase 3
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled267 locationsNCT06337318
Recruiting
Phase 1Phase 2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaGrade 3b Follicular Lymphoma
University of Washington35 enrolled1 locationNCT05455697
Recruiting
Phase 2
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Mantle Cell Lymphoma
Academic and Community Cancer Research United45 enrolled7 locationsNCT04626791